Using economics alongside clinical trials: Why we cannot choose the evaluation technique in advance
Authors: Donaldson, C., Hundley, V., McIntosh, E.
Journal: Health Economics
Publication Date: 01/01/1996
Volume: 5
Issue: 3
Pages: 267-269
ISSN: 1057-9230
DOI: 10.1002/(SICI)1099-1050(199605)5:3<267::AID-HEC209>3.0.CO;2-X
Abstract:When drafting protocols for the use of economic evaluation alongside clinical trials, it is common to have to specify which type of economic evaluation is going to be carried out. Will it be a cost-benefit analysis (CBA), cost-effectiveness analysis (CEA) or a cost-utility analysis (CUA)? It is our contention that prior specification of the appropriate economic technique is not possible, in the majority of cases, until data on effectiveness and cost are actually available. In this letter, we aim to demonstrate the thinking behind our contention and to illustrate this with two case studies; one of a recent randomised trial, the other of a trial currently in progress.
Source: Scopus
Using economics alongside clinical trials: why we cannot choose the evaluation technique in advance.
Authors: Donaldson, C., Hundley, V., McIntosh, E.
Journal: Health Econ
Publication Date: 1996
Volume: 5
Issue: 3
Pages: 267-269
ISSN: 1057-9230
DOI: 10.1002/(SICI)1099-1050(199605)5:3<267::AID-HEC209>3.0.CO;2-X
Abstract:When drafting protocols for the use of economic evaluation alongside clinical trials, it is common to have to specify which type of economic evaluation is going to be carried out. Will it be a cost-benefit analysis (CBA), cost-effectiveness analysis (CEA) or a cost-utility analysis (CUA)? It is our contention that prior specification of the appropriate economic technique is not possible, in the majority of cases, until data on effectiveness and cost are actually available. In this letter, we aim to demonstrate the thinking behind our contention and to illustrate this with two case studies; one of a recent randomised trial, the other of a trial currently in progress.
Source: PubMed
Using economics alongside clinical trials: Why we cannot choose the evaluation technique in advance
Authors: Donaldson, C., Hundley, V., McIntosh, E.
Journal: HEALTH ECONOMICS
Publication Date: 1996
Volume: 5
Issue: 3
Pages: 267-269
ISSN: 1057-9230
DOI: 10.1002/(SICI)1099-1050(199605)5:3<267::AID-HEC209>3.0.CO;2-X
Source: Web of Science
Using economics alongside clinical trials: why we cannot choose the evaluation technique in advance.
Authors: Donaldson, C., Hundley, V., McIntosh, E.
Journal: Health economics
Publication Date: 1996
Volume: 5
Pages: 267-269
ISSN: 1057-9230
Abstract:When drafting protocols for the use of economic evaluation alongside clinical trials, it is common to have to specify which type of economic evaluation is going to be carried out. Will it be a cost-benefit analysis (CBA), cost-effectiveness analysis (CEA) or a cost-utility analysis (CUA)? It is our contention that prior specification of the appropriate economic technique is not possible, in the majority of cases, until data on effectiveness and cost are actually available. In this letter, we aim to demonstrate the thinking behind our contention and to illustrate this with two case studies; one of a recent randomised trial, the other of a trial currently in progress.
Source: Manual
Preferred by: Vanora Hundley
Using economics alongside clinical trials: why we cannot choose the evaluation technique in advance.
Authors: Donaldson, C., Hundley, V., McIntosh, E.
Journal: Health economics
Publication Date: 05/1996
Volume: 5
Issue: 3
Pages: 267-269
eISSN: 1099-1050
ISSN: 1057-9230
DOI: 10.1002/(sici)1099-1050(199605)5:3<267::aid-hec209>3.0.co;2-x
Abstract:When drafting protocols for the use of economic evaluation alongside clinical trials, it is common to have to specify which type of economic evaluation is going to be carried out. Will it be a cost-benefit analysis (CBA), cost-effectiveness analysis (CEA) or a cost-utility analysis (CUA)? It is our contention that prior specification of the appropriate economic technique is not possible, in the majority of cases, until data on effectiveness and cost are actually available. In this letter, we aim to demonstrate the thinking behind our contention and to illustrate this with two case studies; one of a recent randomised trial, the other of a trial currently in progress.
Source: Europe PubMed Central